eribulin
Showing 1 - 25 of 64
Refractory Solid Tumors Trial in Houston (Eribulin, Irinotecan, Temozolomide)
Recruiting
- Refractory Solid Tumors
- Eribulin
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 22, 2023
Breast Cancer Trial in Tampa (Eribulin, Carboplatin)
Completed
- Breast Cancer
- Eribulin
- Carboplatin
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Oct 28, 2022
Leiomyosarcoma, Liposarcoma, Soft Tissue Sarcoma Adult Trial in Taipei (Eribulin, Lenvatinib)
Active, not recruiting
- Leiomyosarcoma
- +3 more
- Eribulin
- Lenvatinib
-
Taipei, Taiwan
- +1 more
Dec 27, 2022
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Boston (Eribulin, Adriamycin,
Active, not recruiting
- Inflammatory Breast Cancer
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Eribulin
- +2 more
-
Boston, Massachusetts
- +1 more
Nov 28, 2022
TNBC - Triple-Negative Breast Cancer Trial in Beijing (Eribulin, anti-PD-1 antibody)
Recruiting
- TNBC - Triple-Negative Breast Cancer
- Eribulin
- anti-PD-1 antibody
-
Beijing, Beijing, ChinaThe Fifth Medical Center of PLA General Hospital
May 29, 2022
Breast Cancer, Metastatic Triple-Negative Breast Cancer Trial in United States (Eribulin, SDX-7320, Placebo)
Recruiting
- Breast Cancer
- Metastatic Triple-Negative Breast Cancer
- Eribulin
- +2 more
-
Basking Ridge, New Jersey
- +6 more
Oct 4, 2022
Angiosarcoma, Epithelioid Hemangioendothelioma Trial in Boston (Eribulin)
Recruiting
- Angiosarcoma
- Epithelioid Hemangioendothelioma
- Eribulin
-
Boston, Massachusetts
- +1 more
Feb 14, 2022
HER2-negative Breast Cancer, Advanced Breast Cancer Trial in Guangzhou (Organoid-guided treatment, Taxane, Capecitabine)
Not yet recruiting
- HER2-negative Breast Cancer
- Advanced Breast Cancer
- Organoid-guided treatment
- +5 more
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Oct 22, 2023
Relapsed Solid Tumors, Refractory Solid Tumors Trial in Aurora, Lexington, Dallas (Eribulin, Irinotecan, Cefixime)
Completed
- Relapsed Solid Tumors
- Refractory Solid Tumors
- Eribulin
- +2 more
-
Aurora, Colorado
- +2 more
Jan 31, 2022
Solitary Fibrous Tumor Trial in Italy (Eribulin)
Recruiting
- Solitary Fibrous Tumor
- Eribulin
-
Palermo, PA, Italy
- +3 more
Oct 29, 2021
Breast Cancer Trial in Spain (Eribulin)
Terminated
- Breast Cancer
- Eribulin
-
Jaen, Jaén, Spain
- +8 more
Aug 26, 2021
Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma Trial in Houston (Atezolizumab, Cobimetinib,
Recruiting
- Recurrent Breast Inflammatory Carcinoma
- Stage IV Breast Inflammatory Carcinoma
- Atezolizumab
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Aug 11, 2021
Breast Cancer Trial in Guangzhou, Shanghai (Camrelizumab, Apatinib, Eribulin)
Active, not recruiting
- Breast Cancer
- Camrelizumab
- +2 more
-
Guangzhou, Guangdong, China
- +2 more
Jul 24, 2021
Breast Cancer Trial in Houston (Paclitaxel, Eribulin, 5-Fluorouracil)
Completed
- Breast Cancer
- Paclitaxel
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Aug 26, 2021
Resolution of Eribulin-Induced Peripheral Neuropathy
Completed
- Locally Advanced or Metastatic Breast Cancer
- Eribulin
-
Amberg, Germany
- +65 more
Jul 12, 2022
HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal
Active, not recruiting
- HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer
- +2 more
- Ribociclib
- Eribulin
-
Ulm, Baden-Württemberg, GermanyUniversity Hospital Ulm -Department of Gynecology
Jul 27, 2022
Metastatic Breast Cancer, Chemo-induced Alopecia Trial in Boston (Paxman Scalp Cooling System, Eribulin, Sacituzumab govitecan)
Recruiting
- Metastatic Breast Cancer
- Chemotherapy-induced Alopecia
- Paxman Scalp Cooling System
- +3 more
-
Boston, Massachusetts
- +1 more
Jan 18, 2022
Triple Negative Breast Cancer Trial in Shanghai (Eribulin, Tislelizumab)
Not yet recruiting
- Triple Negative Breast Cancer
- Eribulin
- Tislelizumab
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
May 29, 2021
Triple Negative Breast Cancer Trial in Shanghai (Personalized treatment guided by mini-PDX and RNA sequencing, Nab paclitaxel,
Recruiting
- Triple Negative Breast Cancer
- Personalized treatment guided by mini-PDX and RNA sequencing
- +5 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 18, 2022
Standard Anti-microtubule Drugs as Assessed by Early Tumor
Recruiting
- Breast Cancer
- Breast Neoplasms
- Taxane
- +4 more
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Dec 10, 2021
Breast Cancer, HER2-negative Breast Cancer Trial in Canada, United States (Paclitaxel, Eribulin, Doxorubicin)
Completed
- Breast Cancer
- HER2-negative Breast Cancer
- Paclitaxel
- +3 more
-
Denver, Colorado
- +19 more
Oct 4, 2021